CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Cardiol Therapeutics (TSE: CRDL)
›
Cardiol Therapeutics (TSE: CRDL) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 1.250 CAD on 19 November 2026, down 13.2% over 52 weeks. Its 52-week range is 1.225 CAD to 3.230 CAD: the price is 61.3% below the high and 2.0% above the low.
Its market capitalisation is 159.61M CAD.
Cardiol Therapeutics reports return on equity of -189.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 25.97M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.